Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 2 2Phase 1/2 2

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Conditions

Papillomavirus Infections 1Cancer Survivor 1

Interventions

Cyclophosphamide 517Bevacizumab 488Carboplatin 424pembrolizumab 387Paclitaxel 385Gemcitabine 372Cisplatin 366Docetaxel 323Rituximab 316Radiotherapy 296Nivolumab 247Doxorubicin 243Dexamethasone 240Fluorouracil 225Capecitabine 214Oxaliplatin 211Erlotinib Hydrochloride 206fludarabine phosphate 201Etoposide 188Cetuximab 186Lenalidomide 177Pemetrexed 176Bortezomib 174Trastuzumab 173Filgrastim 171fludarabine 166Prednisone 166Leucovorin 166Cytarabine 166Irinotecan 161

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Has results × Human Papillomavirus Recombinant Vaccine nonavalent × Clear all
NCT03036930 2026-05-29

Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients

National Cancer Institute (NCI)

Phase 2 Active not recruiting
51 enrolled 10 charts

Papillomavirus Infections

NCT01492582 2021-10-27

Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors

University of Alabama at Birmingham

Phase 2 Completed
1,499 enrolled 11 charts

Cancer Survivor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡